fusion iv pharmaceuticals inc. dba axia …fdagov-afda-orgs/...dl:ifjartmiln-t of healttl and...

7
Dl:ifJARTMilN-T OF HeALTtl AND HUMIUUU:!RVICES ANO OR'JG ,..- DISTilTCT OJYFJCEAIJCRE$9 ,,NO U,s Aogtlc.'l O(tkA I 9'70 I Faircllfld l'Mne"' CA 9'2() 12 lruoJma.11tl1'1: Pl\t.t!I)S) OJl l3. MRJ20 17 ? .... 1MR12'i>l'7 ,:p -1 .. J01Jl4!S6:3 !'#At/£ At""ffi TIT\.E" 'TO WHdM REiPmf'r IS liS$ ' Na'll'icl {NMJ) Vo.bc:d1, 0\'YJlCr i'mia ttAUIJ Fa\1.i.onl\l f11c, Axia PhAAnaceutical - -- -- - 1990 \VesJw¢00 Blvd :8"' ll$ m' . af.I\TE Mfo ZWCoca TYPG QJIODYAJIUIHMl'.tJT IN.:)PgCTBO 'Producer Dru, Produ<:u THIS OOCtJWlttr US'TI:l MA DE BY FOr\ OURI HG THE OF P/>.CIU1Y. INSPGOitON'At. NJO DO r-t<lT Fl.fJPRI!SI : .tn 1\ FlNN.. YOUil <lOMPlt .. IF '(Of tHNit; /IN . OBse!WATICt$, Ofl HA\11t lllP1.£UENI'W, OA I'UJI TO ACTION ttl '1'0 AN (ltJgPJ{VATIOtJ. V<)tJ OltlOOOll llm Ol,tJC::CflQN <l l< \\1111 J411! FCi\ OORIN(3 lUI! OR $1.1Ei t, UT TO fDA Al TI1E .WORESS NJO"'li.. If! 'IOU f.I ,WE MY' C.tJI!Slt ON$, f!t:EA.elltOOTACf FIDA.A.T t•te PJlotm NUt-' AliA .IWO ACIOflM!) J\TIOY!. OO"INCi 1\N IN:Sf.'f().llo.N \1f FlAM (I} 1\'>tJ Lo:i CA DURJNO AN INSPECTION OF YOUR FIRM · wE OBSERVED: OBSERVATION I J- 1 rocedt1res designed t.o pre'llent m:tcrobiologicnl contamlnnUon of drug pl'Q(Iuots puLpOrting to be stet:iJe are .not established. A.. Y ()u did not perform . investigations into the of medill 1111 ste.L'ility fnllt ltes for medlt:l t.JU runs performed in ISO 5 tamlnDl' Flow \Vor'kMatio(l.$ (LAFWs) from (b) (4) TurhtrJity wns observed In the growth promolion med [a.for (b) ( 4) m<:dia fl Unms rnitiattd between (6) (4) b) 4) . Add il . ioually, yoH t1liled to itt vestignte I he rQot of tlte fo Uowi11g stw.-il ity tlu m'¢S durlng .n,ediu till validation runs pr.ior to producing and distr1buting sterile dn1g B . You have never perfonned medea fill validation runs the (b) (4} nud Copphlg mn <lf1ine PennTech Ylfll filling 111achine) Jocatcd in the IS<f.S tilling room. A<:c.oroing to uLog of (o) (4) Repoott?' pdntcd 20Mm'2011. you produced (5) (4) batches of sterile dnrg Qn tho PcnnTccb auto11tated vfal fliHng mttclline between (b) (21) C. You huve not J)el'fol·med 8 Slll.O.ke Pattern Test fn your S: FHler Roomt" where the PennTech at1tom.atetf .. F. CSO Th4cl.-uA Qln, cso 03/2Jh.Ol7 Macccftlnus Dool'J.anoo, W' (.1 C C'll'i}lr"1 tNSPECTION AL 013S:ERVAl iON$ 1 of 7

Upload: nguyenhuong

Post on 16-Mar-2018

216 views

Category:

Documents


4 download

TRANSCRIPT

  • Dl:ifJARTMilN-T OF HeALTtl AND HUMIUUU:!RVICES FOO~ANO OR'JG AOI,Qtft:;JfMT1()f~ ,..-

    DISTilTCT OJYFJCEAIJCRE$9 ,,NOPHON~ Nu~UIE$1U,s Aogtlc.'l Disl'7

    ,:p-1 ~u..mn~

    J01Jl4!S6:3

    !'#At/ At""ffi TIT\.E" Qfi'iNDM~;JV.'Il 'TO WHdM REiPmf'r IS liS$

    ro~ 'Na'll'icl {NMJ) Vo.bc:d1, PliannO.~ 0\'YJlCr

    i'mia ttAUIJ

    Fa\1.i.onl\l l'f~ntt~e-ootic:al-$, f11c, db.~\ Axia PhAAnaceutical

    -~-:r:R""'i'El'..--I~CTIC\'\1 OF YO~ P/>.CIU1Y. '1H~Y ~ INSPGOitON'At. OOSClR.YAtlOt-00~ NJO DO r-t

  • DEP.ARTMSNT Oft Ht!AL'rH AND IWMAN :&f!RVICE!S .1-"001> ~ORIJG AOhtiNJS.fRATJC.1~

    01 l~ICiT C:FICI~ ;'lllii'Ae!tlfllND Pl10'11'. NtltAOC:R ti)S Angeles Distda Office 1m1l-"ain;hHd ~viM,.CA 9-2612 949:8~~000 .

    .lodu:~~ry lnlomuli\att; www.fda.gov/il~lndLJ~try

    0/tTiitt~) OF IN~PfiC'riQN

    1.:1Mt~~r'l017 ~ llMi'11'..1"(1J'

    30UJ~ISQ.j

    :if IXI:l du:ex; IN!IItvtt:lfl\L ro 'PiJ

  • - - -

    "l=tQ Twt C-a.seo < 4 > ( b} (4} Ve.rifieation fo1 (b) (4)

    .tches fo!'

    Tht'ovcd on 2tMarJ7.

    C. Records were iusufficie11t regarding incubation of (o) (4) as 'foitows:

    l) A~Qtding to manufac.turer'sjnstrucll01l3.. required to be nl (D) (4) incubator

  • - - --- - ---- ---

    tJePAA.TMEtfl Of' flEAL1H AND ~iUMAil $!R\IICES FOOO M-ID bRt.JC A~IINISl'RAnotJ

    OA'nl:tSI or.mQ;~GCllr)r~

    Los Ange)e$ Dist1Jct Office

    biSTif:"e1 CfF&CE /...ODREeS liND PHOil NUP~ai!R

    l3Ma.r~027 2'1M111r20l71910l FLiliC!bild Jrvine.. cA 926l~ 9-4?~60$-25100

    30l334U63fllduSir/lllfurmatl.oo: 'W"!W.&1).w/oclil~1.1'Y

    Fl.fllU~~AJ.lF. STRE'2fACDRESS

    fl\lsto.nlV l,llitlrmne~IXknJ:s, Inc:. dba A~a Pfulm,ncculit~l 1990 Woes!wcodBtvd ~tG !35 l'Y-PE:OFESfAilLI8HP,tEtlT tNSF0rn-o- ------ ......:_..--..em'. ~A.U Me ZIP 000&:

    L.()s AA&e!d1

  • DI:PARTM'SNT OP HE:Al'Tl-1 1\Ni> l'fUNAN SERVICES

    ID\id~tJN.o n1LE C4'001MoUAltO ii\fi(i;:ffie~ID'IS ISSUflb -- - ----.- . -~-- - --------

    FIRM t~A11.ii: tlf.lli!ET Ao~~s

    P41Sion IV Phlllrftl-.ceufit:Aas. JiLe. dbR A.xi11 f'hQrmll~utwa.l l99(t Westwood. Blvd Ste llS ~STAi'Ei.N~i:IP-00!! ~-- tri>e~$wwi-f6iirkftmP!!C~'fll~-o------ - -t.oo 1\nje~.s, CA 900Z~4-DSO ?r.

  • .... DEPARTMENTOf' Ht:Al.'rft ANb H1J1'11AN S.ER~CES

    2'000 ;.NO DH.t.IG AOIAINtSnV.OON

    IOI4iRtr.TWiti'ifAoull&~ ANo l)jtoNr.'!'l':rJu= oe..,.. -------,o-:: ~ , ~~er-,.,.E~C!'=': ~,,,= t{---- E~""'cn o,-.-: Tt-::-:otJ ---- ---t IM-:-::T:::-LM AJt~el~Dimi"t Otllce r)Mfl1'2() 1:t. 2J:tvM~Ol1 19101 Faircbild Irviue;, CA. 9UCl FEitltl!.WE:R' 9i')-60t-290\}. ;. 30t3J4iSo3fn V[~1

    ~=--:-:-~o:--~------- - --- OBSSRVADON 7

    Sttiot c.ontrol is not exerc,ised over JabeHng l~ued fo.r use in drug prOO.uct Jabethg a_perations.

    Sp

  • ----

    ------------ ------------

    ' .

    0:14A~Tr.ti:Nf 01 til;At.lH AND tf~'-'AH .SifMCE'S FOOO ANU OAUO MMIM~1AATION

    I.,----,.~-:---.......,.~~""::":':":~=:':"=,------------- - "1'-=-:=~=-::==~-----0IS.TRLCT ~riCE ,\t~ORfiS. PHON!; ~t.tOEFI OATE(S} OF l'i~S'f.:C"flotl

    LA. 483 ~o~ PRElfK.lUS WITtON 04!SCt.~ INSI?!::CTtONAL OBSERVATIONS Page 7 of7

    http://www.fda.gov/medwatch

    APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_1APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_2APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_3APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_4APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_5APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_6APPLIED_FusionIVPharmaceuticalsIncdbaAxiaPharmaceuticals_LACA_483Amend2_03-23-17_Redacted_Page_7